FDA approval for the Retain product has been delayed.
2 reports, 2 independent
Updated Aug 18
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approval for the Retain product has been delayed.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA delayed approval for Retain product.1 source
Specific development regarding the product whose approval has been delayed.1 source
Keep exploring
The entities involved
Related events
- FDA approval enables commercial availability for a product associated with Indianapolis.
- Unregulated products are bypassing official government approval processes.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Litigation regarding FDA approval process.
- FDA and Pfizer are seeking regulatory approval for their products.
Coverage
Newest first; wire copies grouped- GuruFocus.comImmuCell Corp (ICCC) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Margin Expansion ... Product Sales Increase: 18% increase in Q2 2025, 14% increase in H1 2025, and 22% increase over the
- GlobeNewswireImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025 Conference Call Scheduled for Friday, August 15, 2025 at 9:00 AM ET PORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE